Imaging extrachromosomal DNA (ecDNA) in cancer.

Autor: Purshouse K; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Centre for Regenerative Medicine, Institute for Regeneration and Repair & Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK.; Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK., Pollard SM; Centre for Regenerative Medicine, Institute for Regeneration and Repair & Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK.; Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK., Bickmore WA; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. Wendy.Bickmore@ed.ac.uk.

Publikováno v: Histochemistry and cell biology [Histochem Cell Biol] 2024 Jul; Vol. 162 (1-2), pp. 53-64. Date of Electronic Publication: 2024 Apr 16.

Adult brain tumour research in 2024: Status, challenges and recommendations.

Autor: Purshouse K; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK., Bulbeck HJ; Brainstrust, Cowes, UK., Rooney AG; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK., Noble KE; Brain Tumour Research, Milton Keynes, UK., Carruthers RD; Beatson West of Scotland Cancer Centre, Glasgow, UK., Thompson G; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.; Department of Clinical Neurosciences, NHS Lothian, Edinburgh, UK., Hamerlik P; Division of Cancer Sciences, University of Manchester, Manchester, UK., Yap C; Clinical Trials and Statistics Unit, Sutton, UK., Kurian KM; Bristol Brain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK., Jefferies SJ; Oncology Department, Addenbrooke's Hospital, Cambridge, UK., Lopez JS; Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK., Jenkinson MD; University of Liverpool & Walton Centre, Liverpool, UK., Hanemann CO; Peninsula Medical School, University of Plymouth, Plymouth, UK., Stead LF; Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Publikováno v: Neuropathology and applied neurobiology [Neuropathol Appl Neurobiol] 2024 Apr; Vol. 50 (2), pp. e12979.

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Autor: Lee, LY, Cazier, J-B, Angelis, V, Arnold, R, Bisht, V, Campton, NA, Chackathayil, J, Cheng, VW, Curley, HM, Fittall, MW, Freeman-Mills, L, Gennatas, S, Goel, A, Hartley, S, Hughes, DJ, Kerr, D, Lee, AJ, Lee, RJ, McGrath, SE, Middleton, CP, Murugaesu, N, Newsom-Davis, T, Okines, AF, Olsson-Brown, AC, Palles, C, Pan, Y, Pettengell, R, Powles, T, Protheroe, EA, Purshouse, K, Sharma-Oates, A, Sivakumar, S, Smith, AJ, Starkey, T, Turnbull, CD, Várnai, C, Yousaf, N, Team, UK Coronavirus Monitoring Project, Kerr, R, Middleton, G

Publikováno v: The Lancet
Purshouse, K 2020, ' COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments : a prospective cohort study ', The Lancet, vol. 395, no. 10241, pp. 1919-1926 . https://doi.org/10.1016/S0140-6736(20)31173-9
The UK Coronavirus Monitoring Project Team 2020, ' COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study ', The Lancet, vol. 395, no. 10241, pp. 1919-1926 . https://doi.org/10.1016/S0140-6736(20)31173-9

Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d31ab90140c0c66272b3cfafe2ca3b

Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells.

Autor: Purshouse K; MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom.; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Friman ET; MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom., Boyle S; MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom., Dewari PS; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Grant V; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Hamdan A; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Morrison GM; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Brennan PM; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom.; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom., Beentjes SV; MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom.; School of Mathematics, University of Edinburgh, Edinburgh, United Kingdom., Pollard SM; Centre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom., Bickmore WA; MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom.

Publikováno v: ELife [Elife] 2022 Dec 07; Vol. 11. Date of Electronic Publication: 2022 Dec 07.

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.

Autor: Booth S; Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, UK., Curley HM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Varnai C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Centre for Computational Biology, University of Birmingham, Birmingham, UK., Arnold R; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Lee LYW; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Department of Oncology, Oxford University, Oxford, UK., Campton NA; Institute of Translational Medicine, Birmingham Health Partners, Birmingham, UK., Cook G; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK., Purshouse K; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK., Aries J; Barts Health NHS Trust, London, UK., Innes A; Imperial College Healthcare NHS Trust, London, UK., Cook LB; Imperial College Healthcare NHS Trust, London, UK., Tomkins O; Leswisham and Greenwich NHS Trust, London, UK., Oram HS; Leswisham and Greenwich NHS Trust, London, UK., Tilby M; Queen Elizabeth Hospital, Birmingham, UK., Kulasekararaj A; Department of Haematology, King's College Hospital, London, UK., Wrench D; Guys and St Thomas' NHS Foundation Trust, London, UK., Dolly S; Guys and St Thomas' NHS Foundation Trust, London, UK., Newsom-Davies T; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK., Pettengell R; St Georges University Hospitals NHS Foundation Trust, London, UK., Gault A; NCCC Northern Centre for Cancer Care, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK., Moody S; NCCC Northern Centre for Cancer Care, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK., Mittal S; Northampton General Hospital NHS Trust, Northampton, UK., Altohami M; Northampton General Hospital NHS Trust, Northampton, UK., Tillet T; Royal United Hospitals Bath, Bath, UK., Illingworth J; Barking, Havering and Redbridge University Hospitals NHS Trust, Essex, UK., Mukherjee L; Beatson West of Scotland Cancer Centre, Glasgow, UK., Apperly J; Imperial College Healthcare NHS Trust, London, UK., Ashcroft J; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK.; Mid Yorkshire Hospitals NHS Trust, Wakefield, UK., Rabin N; University College London Hospitals, London, UK., Carmichael J; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK., Cazier JB; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Centre for Computational Biology, University of Birmingham, Birmingham, UK., Kerr R; Department of Oncology, Oxford University, Oxford, UK., Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, UK., Collins GP; Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, UK., Palles C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2022 Feb; Vol. 196 (4), pp. 892-901. Date of Electronic Publication: 2021 Nov 10.